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The major group of human immunodeficiency viruses (HIV-1) that comprise the current global pandemic have diversified
during their worldwide spread and may be divided into at least 10 distinct subtypes or clades, A through J. Subtype B
predominates in North America and Europe, subtype E predominates in Southeast Asia, and subtype C predominates in
sub-Saharan Africa. Functional distinctions in long terminal repeat (LTR) architecture among HIV subtypes have been
identified, thus raising the possibility that regulatory divergence among the subtypes of HIV-1 has occurred. In addition to the
transcriptional specificity of the HIV-1 LTR, productive HIV-1 replication is also dependent upon the viral Tat protein.
Therefore, we sought to investigate whether interactions between host signaling pathways and the NF-B regions of different
HIV-1 subtypes, together with subtype-specific interactions between Tat, TAR, and cellular proteins, modulate the efficiency
of HIV-1 clade-specific gene transcription. We demonstrate that the NF-B sites of subtypes B and E both bind NF-B-related
complexes. However, the duplicated B sites of the C subtype do not compete for NF-B binding. Also, clade E Tat protein
possesses the highest transactivation capacity, regardless of the LTR context. Furthermore, preliminary evidence suggests
that the acetylation of subtype-specific Tat proteins may correlate with their transactivation efficiency. © 2002 ElsevierINTRODUCTION
The major group of human immunodeficiency viruses
(HIV-1) that comprise the current global pandemic have
diversified during their worldwide spread. These isolates
can be grouped according to genomic sequences and
divided into at least 10 distinct subtypes or clades
(Korber et al., 1995). Isolates from different subtypes may
differ by 30–40% in amino acid sequence in the Env
region, whereas variation ranges from 5 to 20% within a
particular subtype (Takehisa et al., 1999). The different
subtypes are not distributed evenly throughout the world:
subtype B predominates in North America and Europe,
subtype E predominates in southeast Asia, and subtype
C predominates in sub-Saharan Africa (Zimmerman et
al., 1997). Analysis of the current worldwide distribution
of HIV-1 subtypes has concluded that HIV-1E and HIV-1C
are the most prevalent HIV subtypes in the world (Mon-
tano et al., 1997). At this stage of the AIDS pandemic,
these subtypes are expanding faster and are of greater
global significance than the HIV-1B subtype prevalent in
North America and Europe (Montano et al., 1997). The
relationship between virus subtype, biological proper-
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dressed at Lady Davis Institute for Medical Research, McGill University,77ties, and pathogenicity is unknown, in part because virus
replication studies have been performed almost exclu-
sively with subtype B viruses (Jeeninga et al., 2000).
Recombinations are known to occur between subtype
groups generating mosaic genomes (Carr et al., 1998;
Gao et al., 1998; Robertson et al., 1995). Although cur-
rently no evidence exists for specific subtype variations
affecting virulence or transmission, controversial data
have suggested that subtype E viruses exhibit high rep-
lication rates and virulence in Langerhans cells (Soto-
Ramirez et al., 1996). However, the observations of Pope
et al. (1997) do not support the conclusion that subtype E
strains have a preferential tropism for dendritic cells and
indicate that other explanations for the rapid heterosex-
ual spread of subtype E strains in Asia need to be
considered. Interestingly, high variability in the nucleo-
tide sequence of the long terminal repeat (LTR) region
that encodes the HIV-1 transcriptional promoter has
been observed (Montano et al., 1997, 1998; Verhoef et al.,
1999). Sequence analysis demonstrated a subtype-spe-
cific LTR-enhancer configuration with a low basal tran-
scriptional activity that was strongly increased in the
presence of Tat transactivator protein (Verhoef et al.,
1999). Nucleotide variations within the LTR promoter
region of main subtypes B, C, and E include alterations inScience (USA)
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ulatory elements such as Sp1, USF, and NF-AT binding
sites (Montano et al., 1997, 1998; Jeeninga et al., 2000).
HIV-1 utilizes the NF-B/Rel proteins to regulate tran-
scription through NF-B binding sites in the HIV-1 LTR
(Kwon et al., 1998). We have previously demonstrated
that NF-B is constitutively activated in primary mono-
cytes and myeloid cell lines chronically infected with
HIV-1 through the maintenance of a ternary NF-B/DNA
complex by IB and virus-induced constitutive IKK ac-
tivation (DeLuca et al., 1999). NF-B induces the expres-
sion of multiple cytokine, chemokine, growth factor, and
immunoregulatory genes, many of which aid in HIV-1
replication (DeLuca et al., 1999). Therefore, activation of
NF-B can impact upon HIV-1 replication and pathogen-
esis at many levels, highlighting the potential importance
of altered B sites in the various clade LTRs.
The HIV-1 Tat protein also exhibits amino acid diver-
gence among the different clades, which may influence
its binding and transactivation functions (Montano et al.,
1997, 1998). HIV-1 Tat stimulates transcription from the
LTR promoter through an RNA hairpin element, called the
transactivator protein-responsive region (TAR) (reviewed
in Gatignol and Jeang, 2000; Karn, 1999). The function of
HIV-1 Tat in resting CD4 T lymphocytes depends on
B-responsive elements within the LTR, again demon-
strating the importance of sequence variations of NF-B
sites within the HIV-1 promoter (Hiscott et al., 2001). The
optimal activity of Tat is further dictated by its association
with Tat-associated kinases (TAKs), which include the
RNA polymerase II (RNAPII) C-terminal domain (CTD)
kinase TFIIH and the cellular transcription elongation
factor P-TEFb (Jones, 1997). TAKs affect processive tran-
scription of RNAPII from the HIV-1 LTR promoter (Oka-
moto et al., 1996; Parada and Roeder, 1996; Yang et al.,
1996). Recently, it has become apparent that the cofactor
cyclin T1, a component of P-TEFb, forms a heterodimer
with Tat and is recruited to the TAR (Garber et al., 1998;
Wei et al., 1998). Once bound to the TAR, cyclin T1 and its
associated proteins, particularly the CDK9 kinase, modify
the RNAPII complex to form an elongation-competent
state by phosphorylation of the C-terminal domain of
RNAPII (Cullen, 1998). In addition, Tat-associated histone
acetyltransferases, TAHs (which include p300 and p300/
CBP-associating factor, PCAF), assist functionally in the
activation of chromosomally integrated HIV-1 LTR, pre-
sumably through acetylation of histones (Benkirane et
al., 1998; Marzio et al., 1998). Furthermore, p300 and
PCAF also directly acetylate Tat on Lys50 in the TAR RNA
binding domain and on Lys28 located in the activation
domain, respectively (Kiernan et al., 1999). In the present
study, synergism between the histone deacetylase inhib-
itor trichostatin A and Tat was observed in transcriptional
activation of the HIV-1 LTR. It was also observed that the
B sites of clade B and E LTRs bind NF-B components;
however, the duplicated B sites of the C subtype do not
compete for binding with NF-B sites from HIV-1B or
HIV-1E. Tat E, compared to Tat B or C, possesses the
highest transactivation capacity, either alone or in com-
bination with TNF, regardless of the LTR context.
RESULTS
To analyze the regulatory interactions between the
various HIV-1 LTR regions and the clade-specific Tat
proteins, the LTRs of HIV-1B, HIV-1C, and HIV-1E were
subcloned into the pGL3Basic vector. The selected HIV-
1B, C, and E LTR and Tat sequences represent consen-
sus sequences derived from analysis of more than 20
different strains from HIV individuals for each clade
(Montano et al., 1997). The HIV-1 LTR promoter regions
are schematically illustrated in Fig. 1A, indicating differ-
ences between the HIV-1B LTR versus clade C and clade
E LTRs. Within the clade C LTR, duplication of the NF-B
sites is observed, resulting in two functional NF-B sites
and two putative B sites. In contrast, within the HIV-1E
LTR, one NF-B site in the enhancer region has been
replaced by a binding site for GABP, as previously de-
scribed (Jeeninga et al., 2000). As well, an additional
TATA sequence has been found upstream of the NF-B
sites in the HIV-1 LTR E, but has been demonstrated to
be nonfunctional (Jeeninga et al., 2000). Other point mu-
tations (illustrated as open circles) are located within
other domains of the HIV-1 LTR. Figure 1B depicts the
sequence comparison of the first 72 amino acids of the
HIV-1 clade-specific Tat proteins. HIV-1B Tat is used as a
reference strain since it represents the most widely stud-
ied Tat protein. Known acetylation sites occur at Lys28
and Lys50 within the Tat protein. Other amino acids
representing putative acetylation sites are boxed. Addi-
tional sites are located at amino acids 24, 40, and 53 of
Tat E and at amino acid 19 in Tat C. Figure 1C compares
consensus HIV-1 Tat sequences (Con Tat B, Con Tat C,
Con Tat E) for each of the clades (derived from the Los
Alamos database) versus the HIV-1 Tat sequences used
in this study. As Fig. 1 demonstrates, few alterations are
observed within the selected Tat sequences, highlighting
their value as representatives for each of their respective
clades.
Binding of the NF-B site within the clade B LTR was
compared to the clade E LTR; specific oligonucleotide
probes spanning the LTR region (PR-B B, 5 AGG GGA
CTT TCC GCT GGG GAC TTT CCA G 3; PR-B E, 5 CTA
GGA CTT CCG CTG GGG ACT TTC CAG 3) were used to
examine the nuclear extracts derived from Jurkat cells
treated or untreated with tumor necrosis factor  (TNF)
for the presence and inducibility of NF-B. As observed
in Fig. 2A, lane 2, an inducible protein DNA complex was
observed in Jurkat cells treated with TNF. Supershift
analysis using specific NF-B antibodies revealed that
the complex was partially or completely supershifted by
the addition of p50 and p60 subunit-specific antibodies
(Fig. 2A, lanes 4 and 5). In addition, protein DNA com-
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plexes containing a portion of c-Rel were supershifted by
anti-c-Rel antiserum (Fig. 2A, lane 6). Using a B-E probe,
strong constitutive DNA binding activity was identified in
Jurkat cell extracts. The intensity of the protein–DNA
complex did not change with TNF induction, indicating
that the B-E probe is modified such that it constitutively
binds host cellular proteins. Using supershift analysis
with p50, p65, and c-Rel, it was possible to demonstrate
that the complex observed with B-E contained p50, p65,
and c-Rel (Fig. 2A, lanes 10–12); however, none of the
antibodies produced a complete loss of the major com-
plex. This binding may represent the strong interaction
with GABP, as previously identified by Verhoef et al.
(1999). In Fig. 2B, competition analysis was performed
using different clade-specific oligonucleotides. Induction
of U937 cells for 8 h with Sendai virus (SV) resulted in the
appearance of a protein–DNA complex binding to clade
B NF-B sites (Fig. 2B, lane 2). Using either unstimulated
or SV-induced extracts, competition experiments were
performed using oligonucleotides corresponding to the
NF-B sites of the different HIV-1 LTR clades (B, C, or E
clade). As shown in Fig. 2B, lanes 3 and 4, oligonucleo-
tides B and E efficiently eliminated binding to the B-B
site. Similar results were obtained in extracts from SV-
infected cells in which oligo(B) and oligo(E) competed for
binding to the NF-B site (Fig. 2B, lanes 6 and 7). How-
ever, in both instances HIV-1C oligonucleotide competi-
tor (5 CCT GGG GCG TTC CTG GGG CGT TCC AGG 3)
was unable to compete for the binding observed in U937
cells. Comparable results were obtained in TNF-treated
FIG. 1. (A) Comparison of LTR regulatory elements in HIV-1 clades B, C, and E. Enhancer and promoter elements included in the U3 and R regions
of the LTR and reported to influence viral expression are shown schematically. Sequence variations within NFAT-1, USF, TCF1-, Sp1, NF-B, and the
TATA box that distinguish the C and E subtypes from the B subtype are indicated by the open circles. The conversion of an NF-B site into a GABP
site within the E LTR subtype is shown as an inverted triangle (Verhoef et al., 1999). Mutations in the clade E TAR element are indicated by closed
circles. Also, the duplication of two putative NF-B sites in the clade C LTR is shown in parentheses. (B) Sequence variation in subtype-specific Tat
proteins. Amino acid residues (1–72 aa) in Tat E and C that differ from Tat B are shown. Lys28 and Lys50, which are targets of acetylation by PCAF
and p300, respectively, are indicated by arrows. Additional lysine residues of Tat E and C that may be targets of acetylation are boxed. (C) Comparison
of Tat B, C, and E sequences used in the present study versus known consensus sequences of each clade (derived from the Los Alamos database).
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Jurkat cells (data not shown) and indicate that the dupli-
cated sites of the clade C LTR are not bona fide B
elements. Together these results demonstrate that the
B-B and B-E clade LTR elements are both capable of
binding NF-B subunits; however, NF-B–clade B dem-
onstrates inducible expression and binding of NF-B
subunits consisting of p50, p65, and to a much lesser
extent, c-Rel. In comparison, the B-E element shows
strong constitutive binding and this binding activity could
only be partially competed using antibodies against p50,
p65, and c-Rel. Similarly, the competition analysis would
suggest that the B-B element has greater similarity with
the B-E element, given the ability of B-E to compete for
clade B DNA binding activity.
To analyze the effects of the different clade-specific Tat
proteins on LTR activity, a series of cotransfection experi-
ments was performed in Jurkat T cells and the results of the
luciferase analysis of LTR activity are shown in Fig. 3. For
each combination of LTR and Tat protein, the capacity of Tat
in conjunction with TNF to stimulate the LTR was evalu-
ated. Based on the cumulative data of Fig. 3, several con-
clusions may be reached: the Tat E protein demonstrates
the greatest fold activation, while Tat B shows the lowest,
regardless of the LTR context; LTR C shows the least
inducibility either with TCH alone or in combination with
TNF. However, it should be noted that the basal level of
LTRC activity was approximately threefold higher than that
of LTR B or LTR E, and thus Tat inducibility appears lower.
In contrast to the expectation that homologous LTR–Tat
combinations would preferentially transactivate, the results
of this experiment indicate that the Tat E protein, regardless
of the LTR context, is the strongest transactivator of LTR
activity.
To investigate the possibility that deacetylation of Tat
protein by histone deacetylases may influence Tat-me-
diated LTR activity, transactivation experiments were per-
formed in the presence or absence of trichostatin A
(TSA), a blocker of histone deacetylase activity. As seen
FIG. 3. Tat/TNF synergistic transactivation of HIV-1 B, C, and E
clade LTRs. Jurkat cells were transfected with luciferase promoter
constructs under the control of E, B, or C clade LTRs in the absence ()
or in the presence of plasmids expressing the Tat protein from different
clades (B, C, and E). Sixteen hours posttransfection, cells were incu-
bated with 10 ng/ml of TNF. After 10 h of stimulation, cells were
assayed for luciferase activity. Relative luciferase activity (expressed as
fold induction) is the ratio of luciferase activity between stimulated and
unstimulated cells. Transfection efficiency was normalized to that of
Renilla luciferase. Values are the mean of three independent experi-
ments performed in duplicate. The FLU/RLU ratios for the unstimulated
LTRs were 11.5 for E, 15.5 for B, and 33.8 for C.
FIG. 2. EMSA analysis of the variant NF-B sequences. (A) Jurkat T
cells were stimulated with TNF (10 ng/mL) for 1 h. Nuclear extracts (5
g) were incubated with NF-B sites from clade B (B-B) and E (B-E)
LTRs (lanes 1–6 and lanes 7–12, respectively). The arrow indicates
complex formation of p50, p65, and c-Rel, as determined by supershift
analysis (lanes 4–6 and 10–12, respectively, as indicated by the aster-
isks). (B) U937 cells were infected (lanes 2, 6–8) with Sendai virus (80
HAU/ml) for 8 h; nuclear extracts (5 g) were incubated with the B-B
probe and competition analysis was performed using oligonucleotides
corresponding to the NF-B sites of clade B, C, or E LTRs. Competition
analyses were performed using a 50-fold excess of cold DNA oligo-
nucleotides.
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in Fig. 4, the inhibition of deacetylation by TSA treatment
led to a 3- to 4-fold increase for each clade-specific LTR,
compared to LTRs analyzed in the presence of Tat alone.
For example, the combination of LTR E/Tat E with TSA
treatment produced a 4.4-fold increase compared to LTR
E/Tat E in the absence of TSA treatment. In Fig. 5,
induction of the different LTRs by Tat plus TNF was
analyzed in the presence or absence of TSA. Again, TSA
treatment further stimulated Tat–TNF transactivation of
the LTR 3- to 4-fold depending on the Tat–LTR combina-
tion. For example, TSA treatment stimulated LTR E and
Tat E transactivation by more than 3.5-fold. In all cases,
the transactivator Tat E was the strongest activator of
LTR activity, and its activity was augmented most dra-
matically by TSA.
DISCUSSION
Numerous studies have shown the existence of HIV-1
viruses with mosaic genomes (McCutchan et al., 1999;
Su et al., 2000). To date, little is known about the effect of
inter-subtype recombination of various HIV genomes in
terms of the pathogenesis and replication efficiency of
these viruses. Previous studies have shown that the
LTRs from HIV-1 subtypes B, C, and E contain distinct
sequence arrangements within the critical enhancer el-
ements. HIV-1 subtype C isolates typically contain three
functional NF-B enhancer sites, while subtype B con-
tains two (Montano et al., 1998). These sites serve to
upregulate viral transcription and replication in response
to NF-B/Rel family members in multiple cell types (Co-
nant et al., 1996; Granelli-Piperno et al., 1995; Pahl, 1999;
Hiscott et al., 2001). Within the HIV-1E virus, a switch to
a new binding site specificity from an NF-B to a GABP
site has been described, indicating the loss of a func-
tional NF-B site and the gain of a new specificity (Ver-
hoef et al., 1999). These genetic changes are character-
istic for the respective subtypes and the NF-B to GABP
switch is present in all 18 subtype E sequences reported
to date (Jeeninga et al., 2000). It has been suggested that
subtype E viruses are particularly virulent and replicate
more proficiently than other subtypes in Langerhan cells,
which are potential target cells in heterosexual transmis-
sion (Soto-Ramirez et al., 1996). However, these data
remain controversial (Pope et al., 1997). Such molecular
modification in the LTR may have profound conse-
quences on viral replication, transmission, and dissem-
ination.
In the present study, we observed differential basal
activities of the LTRs of clade B, C, and E HIV-1 viruses
as well as dissimilar transactivation potentials of the
various Tat proteins. Transient transfection assays of
Jurkat T cells indicate that Tat E, regardless of the LTR
context, demonstrates the highest transactivation poten-
tial. This finding corroborates the results of Jeeninga et
al. (1999), in which the replication efficiency of a wild-
type (WT) clade B HIV-1 strain (LAI) was compared with
a molecular clone of the strain in which the WT LTR B
sequence was replaced with a portion of the LTR E
sequence (Jeeninga et al., 2000). The recombinant HIV-
1B/E virus had an increased rate of replication compared
to the WT clade B LAI strain (Jeeninga et al., 2000),
demonstrating that heterologous combinations of clade
viruses may increase viral fitness.
Next, we sought to determine if acetylation of the
FIG. 5. Effect of TSA on Tat/TNF synergism of LTR transcription.
Jurkat cells were transfected with luciferase promoter constructs under
the control of E, B, or C clade LTR enhancer in the presence of plasmids
expressing the Tat protein from different clades (B, C, and E). Sixteen
hours posttransfection, cells were incubated with 10 ng/ml of TNF in
the absence or in the presence of 450 nM TSA. Luciferase activity was
determined as previously described in the legends to Figs. 3 and 4.
FIG. 4. Effect of TSA on Tat-mediated transactivation. Jurkat cells
were transfected with luciferase promoter constructs under the control
of E, B, or C clade LTR enhancer in the presence of plasmids express-
ing the Tat protein from different clades (B, C, and E). Sixteen hours
posttransfection, cells were incubated with 450 nM TSA, a deacetylase
inhibitor, or left untreated. After 10 h of stimulation, cells were assayed
for luciferase activity. Relative luciferase activity (expressed as fold
induction) is the ratio of luciferase activity between stimulated and
unstimulated cells. Transfection efficiency was normalized to that of
Renilla luciferase. Values are the mean of three independent experi-
ments performed in duplicate.
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various Tat proteins plays a role in their transactivation
capacity. It has previously been determined that acety-
lation of Tat is an important regulatory step in proper
functioning of this transactivator. Acetylation of Lys28 by
PCAF enhances Tat binding to CDK9/P-TEFb, whereas
acetylation by p300 of Lys50 dissociates Tat from TAR,
indicating a two-step time-dependent mechanism of Tat
transactivational regulation by TAHs (Kiernan et al.,
1999). With addition of the deacetylase inhibitor trichos-
tatin A, increased transactivation by each of the various
Tat proteins was observed, with Tat E demonstrating the
greatest fold induction. It is interesting to note that in
addition to Lys28 and Lys50, Tat E contains further lysine
residues at positions 24, 40, and 53 that may be subject
to modification. However, it has been recently demon-
strated that TSA plus TNF, but not TSA alone, increased
the expression of an NF-B-dependent reporter gene
through inhibition of histone deacetylase (HDAC) core-
pressor proteins that interact with the p65/RelA subunit
of NF-B (Chen et al., 2001). Therefore the possibility
exists that the greater transactivation seen in the pres-
ence of TSA may be dependent on the acetylation state
of both Tat and NF-B. Further analysis is required to
determine if the various Tat proteins are diversely acety-
lated, i.e., if Tat E demonstrates a greater acetylation
potential than Tat B or C, or if the effects of TSA are
mediated mainly through NF-B. An additional possibility
to explain the high transactivation potential of Tat E is
enhanced interaction with cyclin T1. Sequence variations
between Tat proteins may account for the altered affinity
with and binding of this cofactor, leading to the strong
transactivation observed with Tat E. Currently studies are
under way to determine if the differential transactivation
of the clade-specific LTRs is due to Tat proteins or if the
observed sequence variations within the LTR also play a
major role, since LTR C was not activated well even in
the presence of Tat E.
Variations between subclades of viruses may play an
important role in their pathogenicity. Considerable evi-
dence exists from animal retrovirus models for a role of
LTR enhancer switches in regulating retrovirus-mediated
pathogenicity and oncogenicity (Tsichlis and Lazo, 1991).
Determining the importance of sequence variations
among different clades of the HIV-1 may help to elucidate
the biological consequences of such alterations and
provide new avenues for therapy.
MATERIALS AND METHODS
Plasmid constructions
Tat sequences of HIV-1 clades B, C, and E were pro-
vided by Dr. Montano, Boston University, Boston, Massa-
chusetts. The selected HIV-1B, C, and E LTR and Tat
sequences represent consensus sequences derived
from analysis of more than 20 different strains from HIV
individuals for each clade (Montano et al., 1997). The
selected clade-specific LTR and Tat represent se-
quences closest to consensus sequences found in the
Los Alamos database. Briefly, Tat sequences of HIV-1
clades B, C, and E were subcloned into the pcDNA
3.1/Zeo () vector (Invitrogen) digested with HindIII and
PstI after the addition of adaptors to Tat sequences.
pGL3/LTR B, pGL3/LTR C, and pGL3/LTR E constructs
were created by digesting the 600-bp HIV-1 LTR clade B,
C, or E from p-GalBasic (provided by Dr. Montano) with
KpnI and HindIII and were subcloned into pGL3Basic
(Promega).
Cell culture, transfections, and luciferase assays
Jurkat T cells and U937 monocytic cells were cultured
in RPMI medium (Gibco BRL) supplemented with 10%
fetal bovine serum, glutamine, and antibiotics. Jurkat
cells (106 cells per transfection), were cultured at 5 105
cells/ml for 16 h prior to transfection. HIV-1 LTR (clades B,
C, and E) constructs (1 g) and Tat (clades B, C, and E)
constructs (1.2 g) were transfected with 100 ng of
pRL-tk (Renilla luciferase for internal control) using the
FUGENE 6 transfection reagent (Roche) as indicated by
the manufacturer. Sixteen hours posttransfection, cells
were incubated with 10 ng/ml of TNF. Cells were stim-
ulated for 10 h with TNF and luciferase activity was
measured using the Dual Luciferase Reporter Assay
System (Promega). For deacetylase inhibition assays,
Jurkat cells were incubated with 450 nM trichostatin A
and 10 ng/ml of TNF 16 h posttransfection. After 10 h of
stimulation, cells were assayed for luciferase activity.
Electrophoretic mobility shift assay (EMSA)
Jurkat cells were stimulated with TNF (10 ng/ml) for
1 h, and U937 cells were incubated with Sendai virus (80
HAU/ml) for 8 h. The NF-B DNA binding activity was
determined by collection of nuclear extracts (10 g) from
Jurkat as well as U937 cells and EMSA was performed
using 32P-labeled probes, DNA binding buffer (10 mM
HEPES, pH 7.9, 2% glycerol (v/v), 40 mM KCl, 1 mM EDTA,
pH 8.0, 0.2 mM MgCl2, 1 mM DTT, 0.05 mM PMSF), 0.2%
NP-40, 0.5 g of BSA, and 1 g of poly(dI:dC). Incubation
was performed for 30 min at room temperature using
DNA oligonucleotides corresponding to the (108 to
78) NF-B region of the HIV-1 LTR: PR-B B, 5 AGG
GGA CTT TCC GCT GGG GAC TTT CCA G 3 (108 to
80); PR-B C, 5 CCT GGG GCG TTC CTG GGG CGT
TCC AGG 3 (108 to 81); PR-B E, 5 CTA GGA CTT
CCG CTG GGG ACT TTC CAG 3 (105 to 78) (Mon-
tano et al., 1997). NF-B binding was confirmed using 1
l of anti-p65, anti-p50, and anti-c-Rel antibodies (Santa
Cruz Biotechnology Inc.). Competition analyses were
performed using a 50-fold excess of cold DNA oligonu-
cleotides.
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